Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma.

NCT01641081 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01641081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01641081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
February 28, 2013
Enrollment
174 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

asthma